Until recently, available treatments primarily managed symptoms with only modest effects. New drugs, such as lecanemab and donanemab, have shown promise in slowing the progression of Alzheimer’s ...

Recently, lecanemab and donanemab have been shown to reduce the build-up in the brain of amyloid plaques -- a key characteristic of Alzheimer's disease -- and to slow down progression of the ...

Recently, lecanemab and donanemab have been shown to reduce the build-up in the brain of amyloid plaques – a key characteristic of Alzheimer's disease – and to slow down progression of the ...

The full data from the TRAILBLAZER-ALZ 2 trial of Eli Lilly’s amyloid drug donanemab has confirmed the top-line results reported in May, but also new findings that reinforce its benefits in ...

The reasons for this stagnation have been discussed endlessly here on Think. In short, a combination of cyclical and structural headwinds has paralysed the economy. While cyclical headwinds like high ...

They have long been left out of clinical trials, including recent trials of lecanemab and donanemab, the first drugs against Alzheimer’s that seem to slow the progress of the disease.

But two substances have been found to do the job. These are artificial antibodies called lecanemab and donanemab that bind specifically to beta-amyloid, flagging it for disposal. However ...

The raw data for the world's biggest buyer of natural resources suggests that parts of the economy are performing solidly, but others are struggling, or undergoing structural shifts. However ...

Get up to speed with who now drives for who in Formula 1 for 2025 after one of the biggest upheavals on the grid in recent memory. Twelve months after no seats changed hands over the winter ...

The final race of the 2024 Formula 1 schedule is set for this weekend in Abu Dhabi, but already the global open-wheel racing series has racked up impressive growth in several key demographics.

The success of Leqembi will likely be influenced by the success of its closest competitor, Eli Lilly’s anti-Aβ mAb donanemab. The FDA is expected to decide on donanemab by the end of the first quarter ...

Lilly's chief executive David Ricks would not be drawn on Lilly's pricing plans for donanemab, saying merely that the company intends to "make sure that all of the people millions in the US who ...